Association of Adipose Tissue and Adipokines with Development of Obesity-Induced Liver Cancer

• Published in: International journal of molecular sciences 2021-02, Vol.22 (4), p.2163
• Main Authors: Rajesh, Yetirajam, Sarkar, Devanand
• Format: Article
• Language: English
• Subjects: Adipocytes; Adiponectin; Adipose tissue; Bioaccumulation; Body fat; Carcinogenesis; Carcinogens; Chemoresistance; Cytokines; Dyslipidemia; Energy expenditure; Fatty liver; Food intake; Hepatocellular carcinoma; Inflammation; Insulin; Insulin resistance; Kinases; Leptin; Lipids; Liver; Liver cancer; Liver diseases; Metabolic disorders; Metastases; Obesity; Organs; Review; Therapeutic targets; Tumor microenvironment
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms22042163

Obesity is rapidly dispersing all around the world and is closely associated with a high risk of metabolic diseases such as insulin resistance, dyslipidemia, and nonalcoholic fatty liver disease (NAFLD), leading to carcinogenesis, especially hepatocellular carcinoma (HCC). It results from an imbalance between food intake and energy expenditure, leading to an excessive accumulation of adipose tissue (AT). Adipocytes play a substantial role in the tumor microenvironment through the secretion of several adipokines, affecting cancer progression, metastasis, and chemoresistance via diverse signaling pathways. AT is considered an endocrine organ owing to its ability to secrete adipokines, such as leptin, adiponectin, resistin, and a plethora of inflammatory cytokines, which modulate insulin sensitivity and trigger chronic low-grade inflammation in different organs. Even though the precise mechanisms are still unfolding, it is now established that the dysregulated secretion of adipokines by AT contributes to the development of obesity-related metabolic disorders. This review focuses on several obesity-associated adipokines and their impact on obesity-related metabolic diseases, subsequent metabolic complications, and progression to HCC, as well as their role as potential therapeutic targets. The field is rapidly developing, and further research is still required to fully understand the underlying mechanisms for the metabolic actions of adipokines and their role in obesity-associated HCC.